The Lancet Gastroenterology & Hepatology in conversation with

Marc Rothenberg on a trial of benralizumab in eosinophilic gastritis

The Lancet Group

Marc Rothenberg (University of Cincinnati College of Medicine) discusses a new trial assessing the efficacy and safety of benralizumab in patients with eosinophilic gastritis, and how the surprising findings might change our understanding of eosinophilic gastrointestinal diseases.

Read the full article:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00145-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv